web3: CRV rises to key resistance area, $0.29 becomes short-term focus
Since early August, CRV has continued to rise, with a monthly increase of nearly 25%. After breaking through the previous consolidation range of $0.18 to $0.21, the price has entered the $0.26 to $0.29 area. This region has repeatedly suppressed rebounds in the past and has once again become the key short-term dividing line.
The $0.26 to $0.29 resistance zone draws attention
Currently, the price is repeatedly encountering resistance in the $0.26 to $0.29 area. The article notes that this has historically been a zone with concentrated large positions, and as the price approaches again, selling pressure is also strengthening. The market has pulled back from this area several times, indicating that selling pressure above remains significant.

Open interest rises to $72.5 million
As the price approaches resistance, CRV's open interest has risen to about $72.5 million. This usually means new positions are entering the market, and funds are starting to reposition around key price levels. Whether the price can hold at these highs and break through effectively will determine whether these new positions continue to push the trend higher or increase the risk of a larger pullback.
Above $0.29 will determine if the rebound can continue
If CRV can consistently hold above $0.29, this means buyers are beginning to absorb the supply above, and the price has a chance to further test the $0.33 level. On the other hand, if this position proves to be resistance again, the price may fall back to the previous retest area after the breakout, namely $0.23 to $0.21.
- $0.29: The most immediate resistance level
- $0.33: If broken, the next target area above
- $0.23 to $0.21: Key support zone after the previous breakout
If the pullback continues to expand, $0.18 to $0.19 remains the main demand zone below, also marking the bottom of the previous consolidation phase. If it fails to hold, the current recovery trend will significantly weaken.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.

